Comparison of dosing schemes for thyroid hormone replacement therapy after thyroidectomy
Abstract
Background Current thyroid hormone replacement therapy (THRT) is built on weight-based standard calculation of dose. A novel Poisson regression model, which accounts for seven clinical variables, was recently proposed to improve accuracy of THRT. We aimed to compare the accuracy of estimated THRT dose to reach euthyroid and the difference in predicted dose between the Poisson (scheme A) and the weight-based standard (scheme B) in patients following total thyroidectomy for benign disease.Methods We retrospectively reviewed medical record of patients who underwent total or completion thyroidectomy for benign disease at a single institution between 2011 and 2019. The THRT dose was calculated using both schemes. We compared the difference between calculated THRT and prediction rates for optimal THRT dosing needed to achieve a euthyroid state between dosing schemes. Patients were evaluated for achieving euthyroid state, defined as TSH 0.45-4.5 mIU/L. We also compared dosing error rates (> 25 mcg over- and underdosing) between schemes. Prediction rates were compared by BMI tertiles to account for the effect of BMI extremes in achieving euthyroid state. The difference in predicted dose between schemes was calculated in both the total sample size and patients that met euthyroid. A measure of agreement, Kappa, was used to estimate agreement between dosing schemes.Results A total of 406 patients underwent total thyroidectomy for benign disease, with 184 having sufficient follow up data confirming euthyroid state. Of the 184 patients, 85.9% (n = 158) were women, 81% (n = 149) were Hispanic, and 56.5% (n = 104) were obese with a median BMI of 30.8 kg/m2. Scheme A resulted in a higher, but not statistically significant, accuracy rate (A: 60.3%, n = 111 versus B: 53.8%, n = 99; P = 0.21). Overdosing errors were lower with Scheme A (A:17.9% versus B: 32.1%; P = 0.0025) and less extreme > 25 µg (A: 17.9% versus B: 26.1%; P = 0.08). A trend in improved accuracy in patients with a BMI > 35 kg/m2 was noted (A: 46.9% versus B: 34.4%; P = 0.20). Scheme A also resulted in less overdosing errors in obese patients compared to Scheme B (A: 19.2% versus 45.2%; P = 0.0006). The average difference in predicted dose between schemes was an entire dose difference, mean of 16.0 µg and 15.8 µg for the total and euthyroid samples respectively. Furthermore, for the majority of patients the predicted dose did not match between the two dosing schemes for total and euthyroid samples, 76% (n = 311) and 76% (n = 141) respectively. In patients that achieved euthyroid, agreement between dosing schemes was low to moderate (Kappa = 0.360).Conclusions Lower rates of overdosing were found for scheme A, particularly with obese patients. No statistically significant differences in predicted THRT dose was observed between schemes. The difference in predicted dose between schemes was on average 15 ug, correlating with an entire dose. The consideration of clinical variables other than weight (scheme A) when determining optimal THRT dosing may be of importance to prevent overdoses, with particular clinical relevance in patients with higher BMIs.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Using BMI adjustment of dose, different ways of calculating the relationship between BMI-related doses had different outcomes in relation to the achievement of euthyroidism or overdosing.
“Using BMI adjustment of dose, different ways of calculating the relationship between BMI-related doses had different outcomes in relation to the achievement of euthyroidism or overdosing, respectively (98).”
From ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism (2025) · cites this paper as [98]
Cites
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · see citing works
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567 · see citing works
Chaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30703-1 · Cited by 1,159 · see citing works
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber for the American Association, K. A. (2012) · Thyroid · doi:10.1089/thy.2012.0205 · Cited by 1,053 · see citing works
Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis
Uzzan, B., Campos, J., Cucherat, M., Nony, P., Boissel, J. P., & Perret, G. Y. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954028 · Cited by 398 · see citing works
Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine.
Biondi, B., Fazio, S., Carella, C., Amato, G., Cittadini, A., Lupoli, G., Saccà, L., Bellastella, A., & Lombardi, G. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.77.2.8345037 · Cited by 237 · see citing works
Using Body Mass Index to Predict Optimal Thyroid Dosing after Thyroidectomy
Ojomo, K. A., Schneider, D. F., Reiher, A. E., Lai, N. B., Schaefer, S. C., Chen, H., & Sippel, R. S. (2013) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2012.12.002 · Cited by 70 · see citing works
Levothyroxine absorption in health and disease, and new therapeutic perspectives.
Ianiro, G., Mangiola, F., Rienzo, T. A. D., Bibbò, S., Franceschi, F., Greco, A. V., & Gasbarrini, A. (2014) · PubMed · Cited by 51 · see citing works
Zaborek, N. A., Cheng, A., Imbus, J. R., Long, K. L., Pitt, S. C., Sippel, R. S., & Schneider, D. F. (2018) · Surgery · doi:10.1016/j.surg.2018.04.097 · Cited by 41 · see citing works
Postoperative thyroid hormone supplementation rates following thyroid lobectomy
Wilson, M., Patel, A., Goldner, W. S., Baker, J. J., Sayed, Z., & Fingeret, A. L. (2020) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2020.06.052 · Cited by 39 · see citing works
Papoian, V., Ylli, D., Felger, E. A., Wartofsky, L., & Rosen, J. E. (2019) · Thyroid · doi:10.1089/thy.2019.0251 · Cited by 35 · see citing works
Postoperative thyroid hormone supplementation rates following thyroid lobectomy
Wilson, M., Patel, A., Goldner, W. S., Baker, J. J., Sayed, Z., & Fingeret, A. L. (2020) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2020.07.001 · Cited by 27 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Centanni, M., Duntas, L., Feldt-Rasmussen, U., Koehrle, J., Peeters, R. P., Razvi, S., Trimboli, P., & Virili, C. (2025) · European Thyroid Journal · doi:10.1530/etj-25-0123 · Cited by 38 · see citing works
“Using BMI adjustment of dose, different ways of calculating the relationship between BMI-related doses had different outcomes in relation to the achievement of euthyroidism or overdosing, respectively (98).”
Levothyroxine therapy in thyroidectomized patients: ongoing challenges and controversies
Rossi, L., Paternoster, M., Cammarata, M., Bakkar, S. Y., & Miccoli, P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1582734 · Cited by 11 · see citing works
Chiardi, I., Croce, L., Caccavale, P., Bertini, J., Coperchini, F., Magri, F., Cappelli, C., Trimboli, P., & Rotondi, M. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf417 · Cited by 4 · see citing works
Zheng, H., Lai, V., Lu, J., Hu, D., Kang, J. K., Burman, K. D., Wartofsky, L., & Rosen, J. E. (2022) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2022.11.025 · Cited by 2 · see citing works
Hemmati, M., Tabesh, H., Peyghambari, A., & Bazrafshan, H. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e12797 · Cited by 1 · see citing works
Analysis of options for prescribing hormone replacement therapy after thyroid organ-sparing surgery
Товкай, О. А., Олександрович, П. В., Миколайович, К. Д., Земсков, С., & Kuts, V. V. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.3.2023.1265
A Clinical Audit of Thyroid Hormonal Replacement After Total Thyroidectomy
Mansy, I., Elsenosy, A. M., Hassan, E. M., & Abdelgader, M. Z. (2023) · Cureus · doi:10.7759/cureus.50374
Treatment approaches for co-occurring hypothyroidism and obesity: A systematic literature review
Harini, K. N., & Nilkantham, S. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100665
Levothyroxine dose prediction post-thyroidectomy for differentiated thyroid carcinoma
Ma, L., Xie, Y., Ke, S., Liu, D., Wang, L., Wang, L., & Liu, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1727681
- Authors
- Valenzuela, F., Berrios, L., Robledo, C. A., Snyder, S., Barney, J. M., Reinhart, H., & Romero Arenas, M. A.
- Affiliations
- The University of Texas Rio Grande Valley (US)
- Doctors Hospital at Renaissance (US)
- ORCID
- Venue
- Journal of Surgical Research
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 264
- Pages
- 316-320
- ISSN
- 0022-4804 (ISSN-L)
- OpenAlex
- W3156478362
- Cited by
- 9
- References
- 12
- Citations by year
- 2025: 5 · 2023: 3 · 2022: 1
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Surgical Research (publishedVersion)
- PubMed (publishedVersion)
- ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley) (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- thyroid hormone replacement, total thyroidectomy, euthyroidism, dose accuracy, dosing errors, body mass index, obesity, benign thyroid disease, thyroid-stimulating hormone, hyperthyroidism, hypothyroidism, completion thyroidectomy, kappa agreement
- MeSH terms
- Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Body Weight, Dose-Response Relationship, Drug, Female, Humans, Hypothyroidism, Male, Medication Errors, Middle Aged, Obesity, Retrospective Studies, Thyroid Gland, Thyroid Neoplasms, Thyroidectomy, Thyroxine, Poisson Distribution, Hormone Replacement Therapy, Drug Dosage Calculations, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review